Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer

V Harding(Hammersmith Hospital), Roshan Agarwal(Imperial College Healthcare NHS Trust), Hani Gabra(Royal Children's Hospital), Ho Kwong Li(Hammersmith Hospital), Roekshana Shaboodien(Hammersmith Hospital), Steven Moser(Hammersmith Hospital), Catherine Urch(Hammersmith Hospital), Nikolaos Diamantis(Hammersmith Hospital), Mark Tuthill(Hammersmith Hospital), Elisabetta Fenu(Royal College of Physicians), R. Burt(Hammersmith Hospital), S. Ngan(Hammersmith Hospital), Sarah P. Blagden(Churchill Hospital), Hanine Medani(Queen's University Belfast)
British Journal of Cancer
August 9, 2012
10.1038/bjc.2012.343
Cited by 34

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201